Key result
Statin use in type 2 diabetes is linked to ~2-point higher pancreatic fat fraction.
Why the study?
Statin therapy in type 2 diabetes mellitus may help preserve pancreatic beta-cell function, but whether liver fat fraction and pancreatic fat fraction are affected remained unclear.
Does statin therapy affect the pancreatic and liver fat fractions in patients with type 2 diabetes mellitus?
Cross-Sectional (n=140)
No
Does statin therapy affect the pancreatic and liver fat fractions in patients with type 2 diabetes mellitus?
Absolute Event Rate: 8.4% vs 6.2%
p-value: p=0.021
In patients with T2DM, statin use does not significantly affect liver fat fraction but is associated with variations in pancreatic fat fraction depending on the specific statin type and dose used.
Association of statin use with higher pancreatic fat in T2DM should not alter prescribing; leaves open causality and clinical relevance.
Background/Objectives: It has been shown that the use of statins in patients with type 2 diabetes mellitus (T2DM) worsens hyperglycemia and hemoglobin A1c levels but may help in the preservation of pancreatic β-cell function. The potential role of a high pancreatic fat fraction (PFF) in this process has not yet been clarified. This study aimed to investigate whether the liver fat fraction (LFF) and PFF in T2DM patients is affected by statin therapy. Methods: This cross-sectional study involved a total of 140 T2DM patients, including both those who were receiving (n = 70) and those who were not receiving (n = 70) statin therapy. The mapping of the LFF and PFF utilizing the IDEAL-IQ sequence was conducted in magnetic resonance imaging. Results: In T2DM patients who used statins, the median PFF was higher compared to those who did not use statins (8.4 vs. 6.2%, p = 0.021), while the median LFF was found to be similar (8.4 vs. 8.9, p = 0.572). Variations in PFF were associated with the use of various statins (non-statin group: 6.2 vs. atovastatin: 8.7 vs. rosuvastatin: 3.2 vs. pitavastatin: 9.2, p = 0.004). The multivariable regression analysis indicated that insulin usage decreased log(LFF) by a factor of 0.16-fold (ꞵ ± SE = −0.16 ± 0.05, p = 0.010), and rosuvastatin usage reduced log(PFF) by 0.16-fold (ꞵ ± SE = −0.16 ± 0.07, p = 0.025), irrespective of other risk factors. Furthermore, the use of atorvastatin (ꞵ ± SE = 0.17 ± 0.06, p = 0.011) and pitavastatin (ꞵ ± SE = 0.19 ± 0.07, p = 0.008) were independently associated with an increase in log(PFF). Conclusions: In patients with T2DM, statin use did not show a significant effect on the liver fat fraction, but it caused differences in the pancreatic fat fraction. The observation of a lower pancreatic fat fraction in patients taking a rosuvastatin and atorvastatin dose of 40 mg/day suggests that different types and doses of statins may have varying effects on pancreatic fat accumulation.
No takes yet. Share an insight, caveat, or question.
Parlar et al. (2025) conducted a cross-sectional in Type 2 Diabetes Mellitus (n=140). Statin therapy vs. No statin therapy was evaluated on Pancreatic fat fraction (PFF) (p=0.021). Statin use in patients with type 2 diabetes mellitus was associated with a higher median pancreatic fat fraction compared to non-users (8.4% vs. 6.2%, p=0.021).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: